Safety, Pharmacokinetics, and Pharmacodynamics of SHR7280, a Non-peptide GnRH Antagonist in Premenopausal Women with Endometriosis: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

被引：0
|
作者：
Yuan Li
Ying Zheng
Bing Xu
Linrui Cai
Sheng Feng
Yiming Liu
Zhenyi Zhu
Qin Yu
Hongyan Guo
机构：
[1] Peking University Third Hospital,Department of Obstetrics and Gynecology
[2] Sichuan University,Department of Gynecologic Oncology, West China Second University Hospital
[3] Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University),National Drug Clinical Trial Institute, West China Second University Hospital
[4] Ministry of Education,Clinical Research and Development
[5] Sichuan University,undefined
[6] National Drug Clinical Trial Institution of West China Second Hospital,undefined
[7] NMPA Key Laboratory for Technical Resarch on Drug Products In Vitro and In Vivo Correlation,undefined
[8] Jiangsu Hengrui Pharmaceuticals Co.,undefined
[9] Ltd.,undefined
来源：
Clinical Pharmacokinetics | 2023年 / 62卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1739 / 1748
页数：9
相关论文
共 50 条
  • [1] Safety, Pharmacokinetics, and Pharmacodynamics of SHR7280, a Non-peptide GnRH Antagonist in Premenopausal Women with Endometriosis: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
    Li, Yuan
    Zheng, Ying
    Xu, Bing
    Cai, Linrui
    Feng, Sheng
    Liu, Yiming
    Zhu, Zhenyi
    Yu, Qin
    Guo, Hongyan
    CLINICAL PHARMACOKINETICS, 2023, 62 (12) : 1739 - 1748
  • [2] Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone receptor antagonist, in healthy men: a randomized, double-blind, placebo-controlled phase 1 study
    Xin Li
    Feifei Sun
    Xiaolei Zhang
    Pingping Lin
    Kai Shen
    Yu Shen
    Lingyu Ma
    Yu Cao
    Chenjing Wang
    BMC Medicine, 21
  • [3] Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone receptor antagonist, in healthy men: a randomized, double-blind, placebo-controlled phase 1 study
    Li, Xin
    Sun, Feifei
    Zhang, Xiaolei
    Lin, Pingping
    Shen, Kai
    Shen, Yu
    Ma, Lingyu
    Cao, Yu
    Wang, Chenjing
    BMC MEDICINE, 2023, 21 (01)
  • [4] Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone antagonist in healthy premenopausal women
    Xu, Yi
    Hu, Wei
    Li, Jian
    Jiang, Xin
    Shi, Ping
    Shen, Kai
    Shen, Yu
    Ma, Lingyu
    Cao, Yu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [5] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial
    Jing, Shan
    Xu, Ranchi
    Yang, Kexu
    Liu, Wenfang
    Zhang, Leduo
    Ke, Ying
    Xia, Guangxin
    Lin, Yang
    CLINICAL THERAPEUTICS, 2021, 43 (04) : 735 - +
  • [6] Pharmacokinetics and pharmacodynamics of ISA247 in a Phase III, randomized, multicenter, double-blind, placebo-controlled study
    Wasel, N
    Gupta, A
    Tomi, Z
    Papp, K
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB9 - AB9
  • [7] Dienogest for Treatment of Endometriosis in Chinese Women: A Placebo-Controlled, Randomized, Double-Blind Phase 3 Study
    Lang, Jinghe
    Yu, Qi
    Zhang, Shulan
    Li, Huajun
    Gude, Kerstin
    von Ludwig, Christiane
    Ren, Xiaowei
    Dong, Liying
    JOURNAL OF WOMENS HEALTH, 2018, 27 (02) : 148 - 155
  • [8] Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study
    Zhao, Xue
    Liu, Hongzhong
    Tian, Wei
    Fang, Ligang
    Yu, Mengyang
    Wu, Xiaofei
    Liu, Aijing
    Wan, Ruijie
    Li, Li
    Luo, Jinghui
    Li, Yuqiong
    Liu, Bo
    He, Yu
    Chen, Xiaowen
    Li, Yuan
    Xu, Donghong
    Wang, Hongyun
    Han, Xiaohong
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [9] A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects
    Xie, Panpan
    Abildlund, Morten T.
    Baekdal, Tine A.
    He, Xuemei
    Lyauk, Yassine K.
    Patted, Usha Rani H.
    Ning, Zu
    Shi, Aixin
    DIABETES OBESITY & METABOLISM, 2024, 26 (08): : 3068 - 3077
  • [10] Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies of the Safety, Tolerability and Pharmacokinetics of Naldemedine in Healthy Volunteers
    Fukumura, Kazuya
    Yokota, Takaaki
    Baba, Yuko
    Camilo, Juan
    Ferreira, Arjona
    GASTROENTEROLOGY, 2016, 150 (04) : S537 - S538
12345